Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on therapies for rare cardiopulmonary disease, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). News about Liquidia often centers on its treprostinil‑based portfolio, including YUTREPIA™ (treprostinil) inhalation powder, the investigational L606 treprostinil liposome inhalation suspension, and its role in promoting generic Treprostinil Injection in the United States.
On this page, readers can follow company announcements related to YUTREPIA’s commercial launch, prescription trends and patient starts, as well as updates from ongoing clinical programs such as the ASCENT study in PH‑ILD. Liquidia regularly reports interim clinical data, including safety and exploratory efficacy findings, and provides context on how these results may inform treatment of PAH and PH‑ILD.
Investors and observers will also find coverage of quarterly financial results, revenue contributions from YUTREPIA and Treprostinil Injection, and details of corporate developments disclosed in press releases and SEC filings. These include financing arrangements, manufacturing expansion in Morrisville, North Carolina, and licensing agreements such as the exclusive U.S. license with Vectura for a nebulizer device used with L606.
In addition, Liquidia frequently participates in medical and investor conferences, R&D days and scientific meetings, where it presents new data on YUTREPIA and L606 and discusses its strategy in pulmonary hypertension. This news feed helps track how Liquidia advances its PRINT®‑enabled inhaled therapies, navigates litigation and regulatory milestones, and communicates with the medical and investment communities over time.
Liquidia Corporation (NASDAQ: LQDA) has resubmitted its New Drug Application (NDA) for LIQ861, targeting pulmonary arterial hypertension (PAH). The FDA issued a Complete Response Letter (CRL) in November 2020, citing incompleteness. Following a Type A meeting in January, the new NDA now includes additional chemistry and manufacturing details, but no new clinical data was required. The FDA plans to classify this resubmission as a Class 2, which entails a six-month review cycle. Liquidia is ready for required on-site inspections delayed by COVID-19.
Liquidia Corporation (NASDAQ: LQDA) will announce its first quarter 2021 financial results on May 13, 2021. The company will conduct a conference call at 8:30 a.m. EDT to discuss these results and provide a corporate update. Interested parties can join the call by dialing 1-877-707-8711 domestically or 1-857-270-6219 internationally, using conference code: 2007727. The event will also be available via webcast on Liquidia's website, with an archive for later viewing.
Liquidia Corporation (NASDAQ: LQDA) announced a private placement agreement with accredited investors to sell 8,626,037 shares of common stock at $2.52 per share, raising approximately $21.7 million. The closing is set for today, with David Johnson from Caligan Partners LP joining the board. This funding aims to enhance commercial capabilities for LIQ861 and Treprostinil Injection, supporting growth initiatives. The company has agreed to file a registration statement to register the resale of shares within 180 days post-closing.
Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, from 1:30 to 2:10 p.m. EST. This event can be accessed via a live webcast on Liquidia's website, with a recorded version available for 90 days post-event. Liquidia focuses on pulmonary hypertension treatments and utilizes its PRINT® Technology for developing innovative products like LIQ861 and LIQ865.
Liquidia Corporation (LQDA) announced that the addressable market for generic Treprostinil Injection has more than doubled following FDA clearance of the RG 3ml Medication Cartridge for use with the CADD-MS® 3 pump. This breakthrough allows Treprostinil to be administered subcutaneously, expanding patient access for pulmonary arterial hypertension (PAH) treatment. The cartridge enables the first subcutaneous administration of the generic drug, previously limited to intravenous use.
Liquidia Corporation (NASDAQ: LQDA) reported its financial results for 2020, revealing a significant decrease in revenue to $0.7 million from $8.1 million in 2019. The company's net loss grew to $59.8 million, or $1.76 per share. Financial measures include a more than 40% reduction in annual cash spending planned for 2021, and a confirmed path to submit a response to the Complete Response Letter (CRL) for LIQ861 in mid-2021. Following the integration of RareGen, Liquidia aims to strengthen its commercial presence in pulmonary arterial hypertension (PAH). Cash reserves were at $65.3 million as of year-end 2020.
Liquidia Corporation (NASDAQ: LQDA) will announce its 2020 financial results on March 23, 2021, followed by a webcast and conference call at 8:30 a.m. ET. The call can be accessed via phone or through their website. Liquidia specializes in developing treatments for pulmonary hypertension and other applications using its PRINT technology. Its key product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain management.
Liquidia Corporation (NASDAQ: LQDA) announced the closing of a debt facility with Silicon Valley Bank, providing up to $20.5 million in loans. The initial tranche of $10.5 million has been funded and used to retire existing debt, adding $1 million to Liquidia’s balance sheet. The second tranche of $5 million is contingent on FDA tentative approval for LIQ861 by June 30, 2022, and the final tranche is available upon full approval by December 31, 2022. The facility matures on September 1, 2024, with interest-only payments through March 31, 2023.
Liquidia Corporation (NASDAQ: LQDA) has appointed Damian deGoa as the new CEO, effective immediately, succeeding Neal F. Fowler, who has retired. DeGoa brings extensive healthcare experience, particularly in pulmonary arterial hypertension (PAH). Under his leadership, Liquidia aims to address regulatory concerns for LIQ861, a drug recently acquired from RareGen. The CEO's stock option grant includes 2 million shares, with specific vesting conditions tied to regulatory and commercial milestones.
Liquidia Corporation (NASDAQ: LQDA) has appointed Michael Kaseta as the new Chief Financial Officer (CFO) effective immediately, succeeding Steve Bariahtaris, the interim CFO since August 2020. Kaseta brings extensive experience from his previous CFO roles at Aerami Therapeutics and Aralez Pharmaceuticals, as well as over a decade at Sanofi. CEO Neal Fowler expressed confidence in Kaseta's ability to aid in Liquidia's growth strategy, especially with products like LIQ861 and RareGen on the horizon.